These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
85 related articles for article (PubMed ID: 6117184)
1. Psycho-social aspects of treatment with long-acting neuroleptics in Spain. Conde-Lopez VJ Acta Psychiatr Belg; 1981; 81(2):133-53. PubMed ID: 6117184 [TBL] [Abstract][Full Text] [Related]
2. Long-acting neuroleptics and therapeutic relationship. Pelc I Acta Psychiatr Belg; 1981; 81(2):154-60. PubMed ID: 6117185 [TBL] [Abstract][Full Text] [Related]
3. The use of long-acting neuroleptics in the acute psychoses. Cassano GB; Placidi GF Acta Psychiatr Belg; 1981; 81(2):173-81. PubMed ID: 6117187 [TBL] [Abstract][Full Text] [Related]
4. Some aspects of the French contribution during the past ten years to the study and use of injectable long-acting neuroleptics. Lambert PA; Guinot G; Chabannes JP Acta Psychiatr Belg; 1981; 81(2):103-14. PubMed ID: 6117180 [TBL] [Abstract][Full Text] [Related]
5. Social aspects of therapy with depot neuroleptics in the Federal Republic of Germany. Haring C; Tegeler J; Lehmann E; Ptock WD Acta Psychiatr Belg; 1981; 81(2):189-202. PubMed ID: 6117189 [TBL] [Abstract][Full Text] [Related]
7. [Study of residual levels of delayed-action neuroleptics]. Furet Y; Breteau M; Etienne T Therapie; 1991; 46(2):119-23. PubMed ID: 1675816 [TBL] [Abstract][Full Text] [Related]
8. [Long-acting neuroleptics in the therapeutic relationship. I. General considerations]. Benvenuti P Riv Patol Nerv Ment; 1982; 103(5):235-47. PubMed ID: 6142521 [TBL] [Abstract][Full Text] [Related]
12. [Neuroleptics with prolonged action]. Cervantes León G Neurol Neurocir Psiquiatr; 1976; 17(1):35-45. PubMed ID: 29246 [TBL] [Abstract][Full Text] [Related]
13. The risk/benefit ratio of depot neuroleptics: a Scandinavian perspective. Dencker SJ J Clin Psychiatry; 1984 May; 45(5 Pt 2):22-7. PubMed ID: 6143744 [TBL] [Abstract][Full Text] [Related]
14. If 'atypical' neuroleptics did not exist, it wouldn't be necessary to invent them: perverse incentives in drug development, research, marketing and clinical practice. Charlton BG Med Hypotheses; 2005; 65(6):1005-9. PubMed ID: 16182461 [TBL] [Abstract][Full Text] [Related]
15. Clinical experience and management considerations with long-acting risperidone. Parellada E Curr Med Res Opin; 2006 Feb; 22(2):241-55. PubMed ID: 16466596 [TBL] [Abstract][Full Text] [Related]
16. [Long-acting injectable risperidone: naturalistic study in three hospitals in Aquitaine]. Raignoux C; Dusouchet T; Bret P; Queuille E; Biscay ML; Caron J; Bret MC Encephale; 2007 Dec; 33(6):973-81. PubMed ID: 18789790 [TBL] [Abstract][Full Text] [Related]
17. [Autonomy attitudes in the treatment compliance of a cohort of subjects with continuous psychotropic drug administration]. Baumann M; Trincard M Encephale; 2002; 28(5 Pt 1):389-96. PubMed ID: 12386539 [TBL] [Abstract][Full Text] [Related]
18. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies. Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596 [TBL] [Abstract][Full Text] [Related]
19. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. Kane JM; Leucht S; Carpenter D; Docherty JP; J Clin Psychiatry; 2003; 64 Suppl 12():5-19. PubMed ID: 14640142 [TBL] [Abstract][Full Text] [Related]
20. [Evolution of antipsychotic drug consumption in the autonomous community of Castile and Leon, Spain (1990-2001)]. García del Pozo J; Isusi Lomas L; Carvajal García-Pando A; Martín Rodríguez I; Sáinz Gil M; García del Pozo V; Velasco Martín A Rev Esp Salud Publica; 2003; 77(6):725-33. PubMed ID: 14965064 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]